<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739440</url>
  </required_header>
  <id_info>
    <org_study_id>Birmex-01-2008</org_study_id>
    <nct_id>NCT00739440</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial to Compare Two Anti-scorpion Serums</brief_title>
  <official_title>Randomized Controlled Trial to Evaluate Efficiency and Safety of the Polyvalent Antiscorpion Serum of Birmex Versus Other Commercial Serum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficiency and safety of the treatment against
      sting scorpion, using two serums, one elaborated by Birmex versus other commercial serum
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We consider relevant conduct this study because the poisoning scorpion bite represents a
      public health problem.

      This is a randomized clinical trial, which included 120 subjects of both sexes aged 15 and 60
      years old and residents of the state of Guanajuato, divided into 2 groups: 60 patients
      received antiscorpion serum of Birmex and 60 patients receive other commercial serum.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of signs and symptoms of scorpion envenomation</measure>
    <time_frame>after treatment (expected average of 12 hrs)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the adverse events in every treated child</measure>
    <time_frame>inmediately after treatment and until 5 days later</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Scorpion Sting</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 15 to 60 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 15 to 60 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>serum antiscorpion</intervention_name>
    <description>The dose may be required for the patient according to clinical manifestations and evolution</description>
    <arm_group_label>I</arm_group_label>
    <arm_group_label>II</arm_group_label>
    <other_name>anti-Scorpion venom Serum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sting scorpion

          -  Informed consent

          -  Age 15-60

          -  Either sex

          -  Resident in study area

        Exclusion Criteria:

          -  Previous treatment with gammaglobulin

          -  Blood transfusion at any stage of life

          -  Sensitivity or intolerance to serums antiscorpion or horse products

          -  Pregnancy

          -  Some immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jimenez C Ma. Eugenia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.</affiliation>
  </overall_official>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2008</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scorpion Stings</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

